As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.
Similar Posts
Guidance: Health Institution Exemption for general medical devices
Guidance for health institutions that manufacture general medical devices under the Health Institution Exemption (HIE).
MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause.
MHRA announces proposals to improve access to world’s best medical devices for patients and to boost economic growth in Britain’s med tech sector
The MHRA has now published the government’s response to its public consultation on future routes to market for medical devices – designed to modernise regulation
UK and Singapore launch a regulatory innovation corridor to speed up access to breakthrough health technologies
Patients in the UK and Singapore could gain faster access to cutting-edge healthcare innovations under a new partnership bringing two globally respected regulators together with one of the world’s leading biotech creators.
MHRA Safety Roundup: July 2025
Summary of the latest safety advice for medicines and medical device users
Corporate report: MHRA: policy for handling corporate conflicts of interest
Information about how we handle potential corporate conflicts of interest (COI) between different parts of the Agency.